HIGHLIGHTS
en Cáncer de Próstata

ASCO PROSTATA 2020

Highlights comentados por:
Dra. Nuria Lainez Milagro
Oncóloga médica en CHNavarra. Pamplona, Navarra.
Enfermedad sensible a castración
17 de junio de 2020

Enfermedad sensible a castración

5505. Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).

Enfermedad resistente M0
17 de junio de 2020

Enfermedad resistente M0

5515. Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Enfermedad localizada
17 de junio de 2020

Enfermedad localizada

5504. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).

Enfermedad resistente
17 de junio de 2020

Enfermedad resistente

5567. Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Biomarcadores
17 de junio de 2020

Biomarcadores

5508. Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).